原发性肝癌SBRT研究进展  

Research advances in stereotactic body radiation therapy for primary liver cancer

作　　者：童金龙[1] 郑勤[1] 孙新臣 

机构地区：[1]东南大学附属第二医院放疗科,南京210029 [2]南京医科大学第一附属医院放疗科,210029

出　　处：《中华放射肿瘤学杂志》2017年第2期234-238,共5页Chinese Journal of Radiation Oncology

基　　金：南京市科技计划项目（项目编号：201303014,201503028,201605032）

摘　　要：SBRT杀伤肿瘤细胞的机制可能与常规分割放疗不同，可体现在以下两个方面：单次大剂量照射可使肿瘤细胞膜破坏，释放肿瘤特异性抗原，成为“原位肿瘤疫苗”，继而可激发免疫系统杀灭残余肿瘤；当单次分割剂量〉8～10Gy时，照射1～6h后可通过酸性鞘磷脂酶途径介导血管内皮细胞快速凋亡，进而肿瘤血管闭塞，出现二次肿瘤杀伤效应。本文综述原发性肝癌利用SBRT临床研究进展，旨在了解其是否通过上述机制增加了临床疗效。Stereotactic body radiation therapy （SBRT） adopts different tumor-killing mechanisms from the conventional fractionated radiotherapy. In SBRT, a single high-dose radiation can destroy the membrane of tumor cells and induce the release of tumor-associated antigen, also named in situ tumor vaccine, which stimulates the immune system to kill the residual tumor; a single-fraction radiation with a dose larger than 8-10 Gy can induce rapid apoptosis of vascular endothelial cells via the acid sphingomyelinase pathway at 1-6 hours after radiation, which causes tumor vascular occlusion and secondary tumor-killing effects. In order to understand whether SBRT improves the clinical treatment outcomes via the above mechanisms, this paper reviews the clinical research advances in SBRT for primary liver cancer.

关 键 词：肝肿瘤/放射疗法 放射疗法 立体定向 进展 

分 类 号：R735.7[医药卫生—肿瘤]